Company profile · Biotech & medical
Mycenax Biotech
永昕生物醫藥股份有限公司 · 4726
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
Mycenax specializes in biologics and biosimilars contract development and manufacturing organization (CDMO) services, offering end-to-end solutions from process development to cGMP-compliant manufacturing.[1]
The company provides mammalian and microbial cell process technology platforms, and covers core capabilities including bispecific or multispecific antibodies, antibody-drug conjugates (ADCs), and cell and gene therapies.[1]
Mycenax operates two GMP-compliant facilities to provide manufacturing solutions from drug substance to drug product.[2]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$98m | +41.0% | -15.8% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$4m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | Mycenax Biotech Inc. |
|---|---|
| Chinese name | 永昕生物醫藥股份有限公司 |
| Stock code | 4726 (TPEx) |
| Industry | Biotech & medical |
| Founded | 28 Sep 2001 |
| Listed | 25 Dec 2013 |
| Paid-in capital | NT$2.1bn |
| Chairman | 陳佩君 |
| President | 陳佩君 |
| Headquarters | 7F., No. 66, Shengyi 2nd Rd Zhubei City, Hsinchu County, Taiwan |
| Website | https://www.mycenax.com |
| Official business description | 生物藥之委託開發暨製造服務(CDMO) |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- Annual report 2025 (English), business scope · annual_report · retrieved 04 Nov 2026
- MYCENAX · website · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list